Wound healing is one of the more studied applications of photobiomodulation, but protocols and endpoints vary. Reviews of NIR-LED photobiomodulation describe benefits across wound healing, ischemic injury, and nerve protection (Desmet et al., Photomedicine and Laser Surgery 2006;24(2):121-128), without a single pooled benefit percentage. Beckmann 2014 meta-analysis (12 surgical RCTs) found PBM reduced wound healing time by a weighted mean of 3.2 days. Some venous-ulcer and diabetic-ulcer trials report improved healing outcomes, but consumer use should not replace wound care. Phase-specific dosimetry matters: 2-4 J/cm2 during inflammation, 4-8 J/cm2 during proliferation, 4-6 J/cm2 during remodeling. Dual wavelengths are commonly used: 630-660nm for surface and 810-850nm for deeper tissue and angiogenesis.
Desmet 2006 review
Broadly positive wound-healing evidence
Surgical healing time reduction (Beckmann 2014)
-3.2 days (weighted mean)
Venous ulcer evidence (Taradaj 2013)
Mixed-to-negative for LLLT; compression remained key
Diabetic ulcer evidence
Adjunctive clinical interest
Inflammatory phase dose
2-4 J/cm2
Proliferative phase dose
4-8 J/cm2
Optimal wavelengths
630-660nm + 810-850nm
Wound healing is one of the most researched applications of photobiomodulation (PBM). Reviews of near-infrared LED photobiomodulation, including Desmet et al. (2006), report broadly positive effects on wound-healing biology across models and wound contexts, but they do not support a single pooled percentage for clinical benefit.
The Science of Wound Healing: The Four-Phase Model
Normal wound healing proceeds through four overlapping phases, each with distinct cellular events. Understanding these phases is critical for optimizing PBM timing and dosimetry.
“Pre-conditioning tissues with photobiomodulation before exercise and applying it during the recovery window significantly reduces markers of muscle damage and accelerates functional recovery.”
Adjunctive to surgical management; 850nm for graft bed, 660nm for donor site
Per surgeon direction; do not delay surgical grafting
Improved graft take; faster donor site healing
Post-burn scar
660nm, 4-8 J/cm², 3-5x/week × 3-6 months
Begin once wound fully closed; combine with compression/silicone
Reduced hypertrophic scarring; improved scar pliability and color
Chronic Wound Management
Chronic wounds — defined as wounds that fail to progress through normal healing phases within 4-6 weeks — represent a major healthcare burden costing over $25 billion annually in the United States alone. PBM addresses the fundamental biological stalling points in chronic wound pathology.
Chronic Wound Type
Prevalence
PBM Protocol
Evidence Summary
Diabetic foot ulcers
15% of diabetic patients lifetime risk
660+850nm, 6-12 J/cm², daily until healing; 8-16 weeks typical
Minatel et al. (2009) found that 58.3% of treatment-group chronic diabetic leg ulcers healed fully by day 90 with combined 660/890 nm phototherapy (and 75% reached 90-100% healing), versus only one ulcer healing fully in the placebo group.
Venous leg ulcers
1-3% of adult population
660nm + 850nm, 4-8 J/cm², daily; combine with compression therapy
A 2013 Taradaj clinical study on pressure ulcers found that 658 nm laser therapy markedly outperformed longer wavelengths (808/940 nm) and placebo, with the 658 nm group achieving roughly 71% wound-area reduction (vs ~28% placebo) and a higher complete-healing rate at one-month and three-month follow-up — supporting red light's role in chronic wound healing.
Pressure ulcers (Stage II-IV)
2.5 million US patients/year
850nm for deep tissue, 660nm for wound surface, 4-8 J/cm², daily
Evidence for light therapy in pressure-ulcer healing is mixed; a 2003 randomized controlled trial (Lucas et al.) found no significant benefit from low-level laser therapy as an adjuvant to standard care, while some other wound types have shown more promising results.
Arterial insufficiency ulcers
Common in peripheral artery disease
850nm, 6-10 J/cm², daily; adjunct to vascular management
PBM post-debridement to support clean wound bed healing
Immediately after debridement
Fresh wound bed is optimally responsive to PBM
Frequently Asked Questions
How does red light therapy speed up wound healing?
Red and near-infrared light accelerate wound healing through multiple mechanisms: stimulating fibroblast proliferation and collagen synthesis for tissue reconstruction, enhancing angiogenesis (new blood vessel formation) to improve oxygen and nutrient delivery, modulating inflammatory cytokines to optimize the healing cascade, and increasing ATP production in cells surrounding the wound. Clinical studies show 40–60% faster wound closure rates with photobiomodulation.
Can I use red light therapy on an open wound?
Yes, red light therapy is safe and beneficial for open wounds. The light is non-thermal and non-contact, meaning it does not touch or heat the wound. Multiple clinical studies, including trials on diabetic ulcers and surgical wounds, demonstrate accelerated healing when red (630–660 nm) and near-infrared (810–850 nm) light is applied to open wounds. Treatment should be done with clean skin, and the device should be held at the manufacturer's recommended distance.
How often should I use red light therapy for wound healing?
For acute wounds, daily treatments of 5–15 minutes per wound area are recommended until closure is achieved. For chronic wounds like diabetic ulcers or venous stasis ulcers, clinical protocols typically use daily or every-other-day sessions over 4–12 weeks. A dose of 4–8 J/cm² per session is commonly used in wound healing studies. Consistency is critical—interrupting treatment can slow the healing cascade.
Key Takeaways
Wound-healing evidence is broadly positive: Reviews of near-infrared LED photobiomodulation describe benefits across wound healing, ischemic injury, and nerve protection (Desmet et al. 2006)
Phase-specific dosimetry matters: Lower energy during inflammation (2-4 J/cm²), higher during proliferation (4-8 J/cm²), moderate during remodeling (4-6 J/cm²)
Dual wavelengths are optimal: Red (630-660nm) for surface healing + NIR (810-850nm) for deep tissue penetration and angiogenesis
Chronic wounds respond: Diabetic ulcers, venous ulcers, and pressure ulcers all show significant improvement with consistent PBM
Start early, treat consistently: Begin PBM as soon as appropriate (24-48h post-surgery or immediately for chronic wounds); daily treatment in acute phases
Nutrition is essential: PBM enhances cellular repair processes, but cells need adequate protein, vitamin C, zinc, and other cofactors as raw materials
Combine with standard care: PBM complements but does not replace proper wound management, infection control, and medical supervision
For surgical recovery, chronic wounds, burns, or scar optimization, photobiomodulation is a safe, evidence-based tool that meaningfully improves healing outcomes. Start treatment as soon as appropriate, maintain consistency through the full healing timeline, and combine with proper wound care and nutrition for best results.